Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
CNS-focused news flow for Supernus Pharmaceuticals centers on commercialization and development of treatments for central nervous system diseases. Recurring signals include product-level sales and prescription trends for Qelbree, GOCOVRI, ZURZUVAE and ONAPGO; FDA and supplier updates tied to ONAPGO; and clinical-stage progress for SPN-817 in epilepsy, SPN-820 in depression and SPN-443 in ADHD.
Investors can compare future SUPN updates by separating growth-product demand, collaboration revenue, royalty and licensing contributions, and research and development spending tied to novel CNS product candidates.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced that its management will present an overview and update during the Jefferies Virtual Healthcare Conference on June 2, 2020, at 4:00 p.m. ET. Investors can arrange virtual meetings with management by contacting the conference coordinator. A live webcast of the presentation will be accessible on the company’s website, with a replay available for 60 days post-conference. Supernus focuses on CNS diseases and markets Trokendi XR® and Oxtellar XR® while developing products for ADHD, treatment-resistant depression, and epilepsy.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced receipt of a Paragraph IV Notice Letter from Apotex regarding an Abbreviated New Drug Application for oxcarbazepine extended-release tablets. The company plans to defend its intellectual property rights proactively, having successfully defended Oxtellar XR against previous generic challengers, Actavis and Twi Pharmaceuticals. Currently, Oxtellar XR is protected by nine patents expiring no sooner than 2027. Supernus continues to develop products targeting central nervous system diseases, including candidates for ADHD and treatment-resistant depression.
Supernus Pharmaceuticals reported its Q1 2020 financial results, achieving $95.0 million in total revenue, an 11% increase over 2019. Net product sales were $92.5 million, also rising by 11%. Operating earnings increased to $29.0 million, a 14% increase year-over-year. The company is on track for the launch of SPN-812 pending FDA approval, with a PDUFA date set for November 8, 2020. Additionally, the acquisition of the CNS portfolio from US WorldMeds is expected to close in Q2 2020, enhancing its neurology portfolio and diversifying revenues.
Summary not available.